PolmanCHO’ConnorPWHavrdovaE, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
2.
ButzkuevenHKapposLWiendlH, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry2020; 91(6): 660–668.
3.
Langer-GouldAAtlasSWGreenAJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med2005; 353: 375–381.
4.
PlavinaTSubramanyamMBloomgrenG, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol2014; 76(6): 802–812.
5.
HoPRKoendgenHCampbellN, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol2017; 16(11): 925–933.
6.
Dalla CostaGMartinelliVMoiolaL, et al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol2019; 85(4): 606–610.
7.
WestTWCreeBAC. Natalizumab dosage suspension: Are we helping or hurting?Ann Neurol2020; 88: 1–3.
8.
FoleyJFDeferGRyersonLZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): A randomised, controlled, open-label, phase 3b trial. Lancet Neurol2022; 21(7): 608–619.
9.
VermerschPKapposLGoldR, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology2012; 78: 1690–1696.
10.
BoveRRankinKLinC, et al. Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis. Mult Scler2020; 26(11): 1410–1419.
